CXCL1 and gastric cancer: Recent studies have been demonstrated that the blockade of the receptor with specific inhibitors (150), as well as the inhibition of the recruitment of immune cells via the CXCL1-CXCR2 axis (144), appear a promising therapy for gastric cancer primarily for diffuse subtype (127).